DALLAS, March 9, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Osteotech Inc. (Nasdaq:OSTE). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/OSTE
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Osteotech Inc. (OSTE) is a medical technology company that develops, processes and distributes biologic products focused on the orthopedic, neurosurgical and oral/maxillofacial surgery markets. The Company is focused on creating technology platforms that provides a variety of procedural specific biologic products to address the changing needs of orthopedics and healthcare in general.
Message Board Search for OSTE: http://www.boardcentral.com/boards/OSTE
In the report, the analyst notes:
"Revenue for the three months ended December 31, 2009, was $26.3 million, including $1.0 million from new products, compared with $24.6 million for the three months ended December 31, 2008. The increase in revenue for the fourth quarter of 2009, compared with the same period of 2008, was primarily driven by the $3.3 million in revenue realized from an agreement to license certain areas of the Company's tissue processing technology.
"OSTE announced this week that its MagniFuse(TM) Bone Graft has generated its first $1 million in revenue during the four month period beginning with the limited launch of the product in late October 2009. OSTE began the first phase of its strategic limited launch of MagniFuse with the release of three procedure specific forms for posterior cervical and posterolateral spine fusion and spinal deformity procedures."
To read the entire report, visit: http://www.beaconequity.com/i/OSTE
See what investors are saying about OSTE at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.